As with most MDM2 inhibitors that have so far reached clinical trials, side effects of NVP-CGM097 include thrombocytopenia and neutropenia which would need to be considered in any clinical application in combination with drugs with overlapping toxicity profiles such as CDK4/6 inhibitors [37]. This evidence concerns the gene MDM2 and Decreased total neutrophil count.